» Articles » PMID: 30536424

Evolution of Our Understanding of the Hyperparathyroid Syndromes: A Historical Perspective

Overview
Date 2018 Dec 12
PMID 30536424
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

We review advancing and overlapping stages for our understanding of the expressions of six hyperparathyroid (HPT) syndromes: multiple endocrine neoplasia type 1 (MEN1) or type 4, multiple endocrine neoplasia type 2A (MEN2A), hyperparathyroidism-jaw tumor syndrome, familial hypocalciuric hypercalcemia, neonatal severe primary hyperparathyroidism, and familial isolated hyperparathyroidism. During stage 1 (1903 to 1967), the introduction of robust measurement of serum calcium was a milestone that uncovered hypercalcemia as the first sign of dysfunction in many HPT subjects, and inheritability was reported in each syndrome. The earliest reports of HPT syndromes were biased toward severe or striking manifestations. During stage 2 (1959 to 1985), the early formulations of a syndrome were improved. Radioimmunoassays (parathyroid hormone [PTH], gastrin, insulin, prolactin, calcitonin) were breakthroughs. They could identify a syndrome carrier, indicate an emerging tumor, characterize a tumor, or monitor a tumor. During stage 3 (1981 to 2006), the assembly of many cases enabled recognition of further details. For example, hormone non-secreting skin lesions were discovered in MEN1 and MEN2A. During stage 4 (1985 to the present), new genomic tools were a revolution for gene identification. Four principal genes ("principal" implies mutated or deleted in 50% or more probands for its syndrome) (MEN1, RET, CASR, CDC73) were identified for five syndromes. During stage 5 (1993 to the present), seven syndromal genes other than a principal gene were identified (CDKN1B, CDKN2B, CDKN2C, CDKN1A, GNA11, AP2S1, GCM2). Identification of AP2S1 and GCM2 became possible because of whole-exome sequencing. During stages 4 and 5, the newly identified genes enabled many studies, including robust assignment of the carriers and non-carriers of a mutation. Furthermore, molecular pathways of RET and the calcium-sensing receptor were elaborated, thereby facilitating developments in pharmacotherapy. Current findings hold the promise that more genes for HPT syndromes will be identified and studied in the near future. © 2018 American Society for Bone and Mineral Research.

Citing Articles

Endocrine Perspective of Cutaneous Lichen Amyloidosis: -C634 Pathogenic Variant in Multiple Endocrine Neoplasia Type 2.

Florescu A, Sima O, Nistor C, Ciobica M, Costachescu M, Stanciu M Clin Pract. 2024; 14(6):2284-2299.

PMID: 39585007 PMC: 11587112. DOI: 10.3390/clinpract14060179.


Genetic testing for familial hyperparathyroidism: clinical-genetic profile in a Mediterranean cohort.

Mazarico-Altisent I, Capel I, Baena N, Bella-Cueto M, Barcons S, Guirao X Front Endocrinol (Lausanne). 2023; 14:1244361.

PMID: 37810884 PMC: 10558207. DOI: 10.3389/fendo.2023.1244361.


A Novel Missense Gene Sequence Variation Resulting in Familial Hypocalciuric Hypercalcemia.

Bletsis P, Metzger R, Nelson J, Gasparini J, Alsayed M, Milas M AACE Clin Case Rep. 2022; 8(5):194-198.

PMID: 36189134 PMC: 9508602. DOI: 10.1016/j.aace.2022.05.002.


Novel Glial Cells Missing-2 (GCM2) variants in parathyroid disorders.

Canaff L, Guarnieri V, Kim Y, Wong B, Nolin-Lapalme A, Cole D Eur J Endocrinol. 2022; 186(3):351-366.

PMID: 35038313 PMC: 8859918. DOI: 10.1530/EJE-21-0433.


A case of adrenal Cushing's syndrome and primary hyperparathyroidism due to an atypical parathyroid adenoma.

Newman C, Costello M, Casey M, Davern R, Dinneen K, Lowery A Ther Adv Endocrinol Metab. 2021; 12:20420188211030160.

PMID: 34377432 PMC: 8326812. DOI: 10.1177/20420188211030160.


References
1.
Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

2.
Stephens P, Tarpey P, Davies H, Van Loo P, Greenman C, Wedge D . The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403):400-4. PMC: 3428862. DOI: 10.1038/nature11017. View

3.
Ibanez C . Structure and physiology of the RET receptor tyrosine kinase. Cold Spring Harb Perspect Biol. 2013; 5(2). PMC: 3552510. DOI: 10.1101/cshperspect.a009134. View

4.
Borsari S, Pardi E, Pellegata N, Lee M, Saponaro F, Torregrossa L . Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas. Endocrine. 2016; 55(2):386-397. DOI: 10.1007/s12020-016-0941-6. View

5.
Law Jr W, Heath 3rd H . Familial benign hypercalcemia (hypocalciuric hypercalcemia). Clinical and pathogenetic studies in 21 families. Ann Intern Med. 1985; 102(4):511-9. DOI: 10.7326/0003-4819-102-4-511. View